ASH 2020 | COVID-19: impact on treating and diagnosing ALL
David Marks, MB, MS, FRACP, PhD, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, shares his thoughts on how the COVID-19 pandemic has impacted the care of patients with acute lymphocytic leukemia (ALL) in the UK. Generally, patients have been continuing with therapy, including both transplants and CAR-T therapy. However, there has been a decrease in the number of patients presenting in the clinic and being diagnosed with ALL. The occurrence of COVID-19 infections in patients with ALL remains low but where it is present, treating these patients remains a challenge. He also discusses the prospect of vaccination in patients with ALL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
